FDA delays Alzheimer’s drug for further review in surprise move
Washington Post
Eli Lilly had expected donanemab to be approved this month, but regulators will hold an advisory committee meeting to scrutinize the drug’s safety and effectiveness.
https://www.washingtonpost.com/business/2024/03/08/eli-lilly-alzheimers-donanemab-fda/